Document is current
Any future updates will be listed below
-
Authors
Fu, Wenyu https://orcid.org/0000-0002-4520-1506
Chen, Meng
Wang, Kaidi
Chen, Yujianan
Cui, Yazhou
Xie, Yangli
Lei, Zi-Ning
Hu, Wenhuo
Sun, Guodong
Huang, Guiwu
He, Chaopeng
Fretz, Jackie
Hettinghouse, Aubryanna
Liu, Ronghan
Cai, Xianyi
Zhang, Mingshuang
Chen, Yuehong
Jiang, Nan
He, Minchun
Wiznia, Daniel H.
Xu, Huiyun
Chen, Zhe-Sheng https://orcid.org/0000-0002-8289-097X
Chen, Lin https://orcid.org/0000-0001-7764-9412
Tang, Kanglai
Zhou, Hong
Liu, Chuan-Ju
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01AR062207, R01AR061484, R01AR076900, R01AR078035, R01NS070328)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 14 February 2024
Accepted: 6 August 2024
First Online: 2 January 2025
Competing interests
: The authors declare no competing interests. Patents have been filed by NYU that claim Tau as a low-affinity receptor of GCs and targeting Tau to overcome the side effects of GCs.
